IP Library › Patent Application 16220276
Patent Application
App. No. 16/220,276

ESCALATING DOSING REGIMEN FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/220,276
Abstract

The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.

Claims (3)

1 . A controlled release composition for treating obesity, diabetes, sleep apnea, or a related condition in a subject comprising:

an effective amount of topiramate and phentermine.

2 . A method for effecting weight loss in a subject, comprising administering to the subject continually over a significant period of time a daily dose of phentermine in combination therewith a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jan 6, 2021
From: U.S. BANK NATIONAL ASSOCIATION
To: VIVUS, INC.
Reel/Frame 054835/0633 →
SECURITY INTEREST Recorded Sep 30, 2019
From: VIVUS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 050570/0289 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2018
From: NAJARIAN, THOMAS; TAM, PETER Y.; WILSON, LELAND F.
To: VIVUS, INC.
Reel/Frame 047790/0011 →